Michael Davidson to 1-Alkyl-2-acetylglycerophosphocholine Esterase
This is a "connection" page, showing publications Michael Davidson has written about 1-Alkyl-2-acetylglycerophosphocholine Esterase.
Connection Strength
0.952
-
Lp-PLA2: A new target for statin therapy. Curr Atheroscler Rep. 2010 Jan; 12(1):29-33.
Score: 0.308
-
Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008 Jun 16; 101(12A):41F-50F.
Score: 0.277
-
Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008 Jun 16; 101(12A):51F-57F.
Score: 0.277
-
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008 Apr 29; 51(17):1632-41.
Score: 0.069
-
Peripheral artery disease, biomarkers, and darapladib. Am Heart J. 2011 May; 161(5):972-8.
Score: 0.021